Biotech / Medical
An SI Board Since March 2010
Posts SubjectMarks Bans Symbol
462 34 0 OMER
Emcee:  Bradpalm1 Type:  Unmoderated
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR (G-protein coupled receptor) program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
462[graphic]Julius Wong-May 12
461Omeros Corporation: Substantial Value Added To The HSCT-TMA Franchise seekingalJulius Wong-April 29
460>> Snicker << Message 31555019scaram(o)uche-April 3
459Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill Julius Wong-March 22
458Crickets...... clinicaltrials.govscaram(o)uche-March 12
457721 fails to get priority review in Europe in a couple of indications. Recommentuck1March 2
456What's a mere five years, Greg? That GPCR franchise is just awesome, a realscaram(o)uche-March 1 -- Clinical Entry Planned for Second Half of 2013 -- From todascaram(o)uche-March 1
454Disingenuous, Greg. Until it's here, it ain't...... clinicaltrials.govscaram(o)uche-March 1
453>> Patient enrollment is expected to begin early next month << Goesscaram(o)uche-February 22
452Omeros gets panned Finally, shares of Omeros plunged nearly 18%. The small bioteJulius Wong-February 15
451I haven't been a shareholder. Just bought a small stake. Greg has over proscaram(o)uche-February 14
450Looks like there was an opportunity to make money here. [graphic]Alejandroo Green-January 25
449SEATTLE--(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) todaynigel bates-January 3
448Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use Wong-12/13/2017
447Press Release Omeros Corporation to Announce Third Quarter 2017 Financial ResulBiotech Jim-11/6/2017
446Was curious about sales of Omridia. In the area I reside, it does not seem to beD.Lu-11/6/2017
445Bloomberg has this to say last week for products coming up for Pass Through StatBiotech Jim111/5/2017
444I just saw on Twitter that AF is now saying Omridia will lose Medicare pass-thoutuck-11/3/2017
443Deleted Mistaken PostBulbaMan-9/26/2017
442On watch for clear above 21.59. [graphic]hollyhunter-9/20/2017
441OMER responds to AF, a one time event? Some )MS 721 trials info updated here. Biotech Jim-8/23/2017
440A bit different. Prices at 22.75, and asks pop up below that. Decent pricing, scaram(o)uche-8/15/2017
439Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference SEATTLE--(BUHoward Williams-8/10/2017
438OMER short volume volumebot.comJulius Wong18/9/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.